Yahoo! Finance Canada report covering Electromed Inc. (ELMD) market action, institutional positioning, and fundamental catalysts.
Why ELMD Stock slipped -1.04% Today — RQD Quant Desk Flash
Electromed Inc. (ELMD) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ELMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Electromed Inc. (NYSE: ELMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $26.76 (-1.04% 1D, market cap $224.1M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, ELMD ranks #143 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ELMD compare to FOCL and CV in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), ELMD carries a Roarable C (63/100 RQD), trailing P/E of 30.4x, gross margin of 78.1%, and ROIC of 24.1%. By comparison, FOCL (EDAP TMS S.A.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $192.1M) and CV (CapsoVision Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $363.3M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while ELMD leads on capital efficiency (24.1% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ELMD?
▼
Per ELMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001488917), Electromed Inc. generated $64.0M in revenue (+17.0% YoY), $7.5M in net income, and $11.1M in free cash flow against $54.9M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (78% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 17.64 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
SEC XBRL FY 2025 (10-K): 17.4% FCF Margin ($11.1M FCF) & 78.1% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
⚔️ Adversarial Opposing Case: Why the ELMD Bull Thesis Could Fail
Even with a 63/100 (C) score, ELMD faces multiple-compression risk if 30.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 75.6% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($27.87) or 200D SMA ($31.27) invalidates the momentum regime and cuts Target Base ($27.36) toward Bear Floor ($21.34).
Why ELMD Stock slipped -1.04% Today — RQD Quant Desk Flash
Electromed Inc. (ELMD) slipped -1.04% to $26.76, trading at 15% of its 52-week range ($23.01 – $47.4). Solid 78% profit margin (24% return on capital), mixed timing at 30x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 15% of its 52-week range ($23.01 – $47.4) with RSI-14 at 43.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6% around $26.76 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 78.1% gross margin and $11.1M annual free cash flow.
TradingView report covering Electromed Inc. (ELMD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Electromed Inc. (ELMD) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Electromed Inc. (ELMD) market action, institutional positioning, and fundamental catalysts.
Investing.com UK report covering Electromed Inc. (ELMD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Electromed Inc. (ELMD) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Electromed Inc. (ELMD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Electromed Inc. (ELMD) market action, institutional positioning, and fundamental catalysts.
Scheduled RQD Strong Buys & Whale Accumulation Briefing (ELMD Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
ELMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +17.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ELMD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ELMD. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELMD)
1. Head-to-Head Health Care Peer Comparison (ELMD vs. FOCL, CV, HSDT, VANI)
Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Electromed Inc. (ELMD) ranks #143 by composite RQD confidence (63/100, grade C) and #558 by equity capitalization ($224.1M). Within this direct 5-issuer industry benchmark cohort, VANI leads on earnings valuation at 3.9x trailing P/E, while ELMD leads on capital efficiency and profitability with 24.1% ROIC and 78.1% gross margin. ELMD currently leads its immediate peer cohort in composite quantitative strength at 63/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ELMD
ACTIVE
Electromed Inc. | C | 63/100 | 30.4x | 78.1% | 24.1% | -1.04% | $224.1M | Benchmark Subject |
| FOCL EDAP TMS S.A. | E | 28/100 | — | 42.5% | -35.0% | +3.83% | $192.1M | /focl-vs-elmd → |
| CV CapsoVision Inc. | D- | 43/100 | — | 52.9% | -35.0% | -1.46% | $363.3M | /cv-vs-elmd → |
| HSDT Solana Company (Class A) | E | 31/100 | — | 96.0% | -35.0% | -3.59% | $135.5M | /hsdt-vs-elmd → |
| VANI Vivani Medical Inc. | E | 28/100 | 3.9x | — | -35.0% | 0.00% | $98.3M | /vani-vs-elmd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001488917In its most recent audited fiscal period (FY2025, filed 2025-06-30), Electromed Inc. (ELMD) reported GAAP revenue of $64.0M (+17.0% vs. FY2024 revenue of $54.7M , and +33.1% cumulative change since FY2023) , GAAP net income of $7.5M, operating cash flow of $11.4M, and free cash flow of $11.1M (+26.8% YoY). On the balance sheet, ELMD closed FY2025 with $54.9M in total assets against $0 in total debt (Altman Z-Score: 17.64, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $64.0M | $7.5M | $11.4M | $11.1M | $54.9M | — |
| FY2024 (FY) | 2024-06-30 | $54.7M | $5.2M | $9.1M | $8.8M | $52.3M | — |
| FY2023 (FY) | 2023-06-30 | $48.1M | $3.2M | $1.3M | $1.3M | — | — |
3. ELMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ELMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Electromed Inc. (NYSE: ELMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $26.76 (-1.04% 1D, market cap $224.1M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, ELMD ranks #143 in composite RQD confidence.
How does ELMD compare to FOCL and CV in the Health Care sector?
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), ELMD carries a Roarable C (63/100 RQD), trailing P/E of 30.4x, gross margin of 78.1%, and ROIC of 24.1%. By comparison, FOCL (EDAP TMS S.A.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $192.1M) and CV (CapsoVision Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $363.3M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while ELMD leads on capital efficiency (24.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ELMD?
Per ELMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001488917), Electromed Inc. generated $64.0M in revenue (+17.0% YoY), $7.5M in net income, and $11.1M in free cash flow against $54.9M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (78% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ELMD trading relative to its 50-day, 200-day, and 52-week technical levels?
ELMD last traded at $26.76 (-1.04% on volume of 52,512 shares), positioning the stock -3.98% below its 50-day simple moving average ($27.87) and -14.42% below its 200-day simple moving average ($31.27). Across its 52-week range of $23.01 to $47.40, ELMD sits at the 15.4% percentile with a 14-day RSI of 43.3 (NEUTRAL RANGE) and an implied next-earnings move of ±6.0% ($25.15 to $28.37).
ELMD — Electromed Inc.: What the Facts Mean to a Prospective Investor
1. Roarable Rating Brief: What This Means to a Prospective Investor
ELMD scores 65 out of 100 (grade C, verdict "Roarable Hold — Fair / Balanced Risk-Reward"). The five pillars break down as follows:
- Fundamental Cash Engine: 17 / 20. this pillar reflects ROIC of 24.1% and an FCF yield of 4.85%. This is the strongest operating signal in the rating and suggests the business generates meaningful returns on the capital it employs.
- Whale 13F Flow: 6 / 20. This pillar covers institutional accumulation and options positioning. The low score indicates limited evidence of institutional conviction in the source data.
- Insider Conviction: 16 / 20. this reflects SEC Form 4 and Congressional PTR cluster flow.
- Macro Regime Fit: 8 / 20. this pillar reflects a Beta of 1.0 and sector sensitivity. The weak score indicates the stock's fit with the current macro regime is limited.
- Forensic Balance Sheet: 18 / 20. this pillar reflects an Altman Z of 17.64, a Piotroski F of 8/9, and Debt/Equity of 0.5. This is the second-strongest pillar and suggests low solvency risk.
For a prospective investor, the picture is mixed. Cash generation and balance-sheet strength are the clearest supports for the rating. Institutional flow and macro fit are the weakest, meaning the stock has less external confirmation and sensitivity to market regime that could cut either way. Valuation metrics (P/E TTM of 30.4, EV/EBITDA of 21.8) sit at levels that, per the market data, already reflect substantial expectations relative to current earnings per share of 0.91. The "Hold" verdict reflects balanced rather than asymmetric risk-reward based on these inputs.
2. Business Model, Unit Margins & SEC Financial Trajectory
Electromed Inc. (ELMD) is a NYSE-listed issuer in the Health Care sector, operating within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry,. Per the market data, gross margin is 78.1%, operating margin 15.1%, and net margin 11.8%. —
Revenue rose from $48.1M (FY 2023) to $64.0M (FY 2025), with net income increasing from $3.2M to $7.5M over the same span. Operating income and free cash flow both expanded across the three reported periods. Per the market data, ROIC is 24.1%, Altman Z-Score is 17.64, and Piotroski F-Score is 8/9 (the latter two ). Debt/Equity is 0. Cash declined from $16.2M (FY 2024) to $13.8M (FY 2025) .
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case: Cash generation is strong, with ROIC of 24.1%, FCF yield of 4.85%, and revenue growing from $48.1M to $64.0M over FY 2023–FY 2025. With Fundamental Cash Engine at 17/20 (ROIC 24.1%, FCF yield 4.85%) and Institutional Whale Flow at 4/20, sustained execution supports upside toward the top of the $23.01 – $47.40 52-week range.
- 🐻 Primary Bear Case: Institutional flow scores just 6 / 20 and macro fit 8 / 20, while the stock trades at 30.4x TTM P/E with a Beta of 1.0. Investors must weigh 30.4x trailing P/E and 21.8x EV/EBITDA against 15.1% operating margins and a 1.00 macro beta if sector demand softens.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The one investor-relevant watch item from the news feed is the scheduled Q1 Fiscal 2027 report on November 10, 2026, which per the news feed is a near-term event; its downstream effects are not described in the source data.
- Key Question #1: What drove the CEO exit referenced in the LD Micro Main Event coverage, and what is the succession plan?
- Key Question #2: What were the Q1 Fiscal 2027 results expected on November 10, 2026, and how do they compare with prior-period trends?
- Key Question #3: What is the period-level debt and EPS history, given that these fields are N/A in the financials?
ELMD Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Electromed Inc. (ELMD) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Electromed Inc. (ELMD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Electromed Inc. (ELMD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Electromed Inc. (ELMD) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Electromed Inc. (ELMD) market action, institutional positioning, and fundamental catalysts.
Investing.com UK report covering Electromed Inc. (ELMD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Electromed Inc. (ELMD) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Electromed Inc. (ELMD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Electromed Inc. (ELMD) market action, institutional positioning, and fundamental catalysts.
ELMD Bull vs. Bear Conversation Board — What's Your Call at $26.76?
Cash generation is strong, with ROIC of 24.1%, FCF yield of 4.85%, and revenue growing from $48.1M to $64.0M over FY 2023–FY 2025.
Long ELMD at $27.04 targeting $32.45. Cash generation is strong, with ROIC of 24.1%, FCF yield of 4.85%, and revenue growing from $48.1M to $64.0M over FY 2023–FY 2025.. Institutional whale score is 4/20 and the risk/reward vs. the $23.01 52-week low is skewed heavily in favor of bulls.
Both sides have a point here — ELMD's 18/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Institutional flow scores just 6 / 20 and macro fit 8 / 20, while the stock trades at 30.4x TTM P/E with a Beta of 1.0.
Fading this rally in ELMD at $27.04. Institutional flow scores just 6 / 20 and macro fit 8 / 20, while the stock trades at 30.4x TTM P/E with a Beta of 1.0.. With a beta of 1.0 and the stock sitting at $27.04 (52-wk range $23.01–$47.40), the easy multiple expansion is already priced in.